TrialPath
Recruiting

Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression

NCT07809906 · Orum Therapeutics USA, Inc.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Phase 1 First-in-Human Multi-Region Clinical Trial of ORM-1153 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Other Hematological Malignancies With CD123 Expression
About this study
The goal of this Phase 1 clinical trial is to understand whether a new experimental treatment, called ORM-1153, will be a safe and possibly effective treatment option for participants with blood cancers such as Acute Myeloid Leukemia (AML) which have a particular protein (called Cluster of Differentiation 123 or CD123) on the cancer cell's surface. Phase 1 studies are designed to find a safe and effective dose. Participants will be receiving ORM-1153 at the defined study frequency as an infusion into the vein. They will need to visit the clinic frequently during the first few months of treatment.
Eligibility criteria
Inclusion Criteria: * Adults ≥18 years of age (or ≥19 years of age according to local regulatory guidelines) at the time of signature of the informed consent form. * Documented diagnosis of relapsed or refractory AML with any detectable level of CD123 as evaluated by local assessment. * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 * Adequate organ and coagulation function. Exclusion Criteria: * Diagnosed with Acute Promyelocytic Leukemia. * Systemic antineoplastic agent therapy given within 14 days or 5 half-lives prior to the first dose of ORM-1153 (whichever is shorter). * Hematopoietic Stem Cell Transplantation within 3 months of the first dose of ORM-1153. * Total White Blood Cell count \>25,000/µL.
Study design
Enrollment target: 42 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-09-23
Estimated completion: 2029-12
Last updated: 2026-11-02
Interventions
Drug: ORM-1153
Primary outcomes
  • • Optimal Biological Dose(s) of ORM-1153 (Approximately 24 months)
  • • Incidence of Dose Limiting Toxicities (DLTs) (Approximately 24 months)
  • • Incidence of Treatment Emergent Adverse Events (TEAEs) (Approximately 24 months)
Sponsor
Orum Therapeutics USA, Inc. · industry
Contacts & investigators
ContactOrum Therapeutics USA, Inc. · contact · ClinicalTrials@orumrx.com · 617-714-9597
All locations (2)
START - MidwestRecruiting
Grand Rapids, Michigan, United States
MD Anderson Cancer CenterNot Yet Recruiting
Houston, Texas, United States
Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression · TrialPath